Activated Clotting Time During Unfractionated Heparin-Supported Coronary Intervention: Is Access Site the New Piece of the Puzzle?

[1]  J. Abbott,et al.  Association Between Maximal Activated Clotting Time and Major Bleeding Complications During Transradial and Transfemoral Percutaneous Coronary Intervention. , 2018, JACC. Cardiovascular interventions.

[2]  S. Windecker,et al.  Developing drugs for use before, during and soon after percutaneous coronary intervention , 2016, Expert opinion on pharmacotherapy.

[3]  R. Lopes,et al.  Relation of Activated Clotting Times During Percutaneous Coronary Intervention to Outcomes. , 2016, The American journal of cardiology.

[4]  P. Jüni,et al.  Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[5]  Sunil V. Rao,et al.  Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial , 2015, The Lancet.

[6]  Sunil V. Rao,et al.  Activated Clotting Time and Outcomes During Percutaneous Coronary Intervention for Non–ST-Segment–Elevation Myocardial Infarction: Insights From the FUTURA/OASIS-8 Trial , 2015, Circulation. Cardiovascular interventions.

[7]  G. Biondi-Zoccai,et al.  Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  Sunil V. Rao,et al.  Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. , 2011, JACC. Cardiovascular interventions.

[9]  S. Rinfret,et al.  Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. , 2009, The American journal of cardiology.

[10]  S. Steinhubl,et al.  Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. , 2008, European heart journal.

[11]  S. Steinhubl,et al.  Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention , 2004, Circulation.

[12]  G. Stone,et al.  Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. , 2003, The American journal of cardiology.

[13]  C. Cannon,et al.  Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). , 2003, The American journal of cardiology.

[14]  G. Levine,et al.  Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. , 2003, Journal of the American College of Cardiology.

[15]  Deepak L. Bhatt,et al.  Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials , 2001, Circulation.

[16]  J. Ferguson,et al.  The use of activated clotting times to monitor heparin therapy during and after interventional procedures , 1994, Clinical cardiology.

[17]  C. Gaos,et al.  Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.

[18]  G. Stone,et al.  Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.